Merck KGaA Q3 2026 Results: Pimjetmi FDA Approval and Silence Therapeutics Deal Back a Raised Full-Year Outlook
Merck KGaA Q3 2026 results show 5.1% organic sales growth to €5.6 billion, strong Process Solutions and Rare Diseases performance, the Pimjetmi FDA approval, and a raised full-year 2026 outlook.
Novartis Rhapsido CIndU Data: Remibrutinib Shows Sustained Efficacy Through Week 52 in Phase III RemIND Study
Novartis reported 52-week Phase III RemIND results for Rhapsido (remibrutinib) in chronic inducible urticaria. Response rates held through Week 52 across symptomatic dermographism, cold urticaria and cholinergic urticaria, and additional regulatory submissions are planned.
Amgen Dazodalibep Phase 3 OASIZ-301 Results Show Systemic Disease Activity Gains in Sjögren’s Disease
Amgen announced Phase 3 OASIZ-301 results for dazodalibep in Sjögren’s disease on November 11, 2026. Both dosing regimens met the primary ESSDAI endpoint at Week 48, and full data will go to ACR Convergence 2026.
Novo Nordisk World Diabetes Foundation Commitment: Pledges USD 200 Million for Diabetes Prevention and Care, 2027–2036
Novo Nordisk has committed USD 200 million over ten years (2027–2036) to the World Diabetes Foundation to strengthen diabetes prevention and care in low- and middle-income countries, announced ahead of World Diabetes Day.
Charles River Frontage Acquisition: Charles River Laboratories to Buy Frontage’s Bioanalysis and DMPK Businesses for About $470 Million
Charles River Laboratories (NYSE: CRL) has agreed to acquire Frontage Holdings’ bioanalysis and DMPK operations in Exton, Pennsylvania for about $470 million in cash, plus up to $75 million in contingent payments. Closing is expected in the first half of 2027.
Eli Lilly and Company’s Foundayo Sleep Apnea Phase 3 ATTAIN-OSA Results Show Up to 44% Fewer Breathing Interruptions
Eli Lilly’s Phase 3 ATTAIN-OSA program found that oral Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity at 52 weeks in adults with obesity or overweight. Lilly plans an FDA submission by the end of 2026.
Eli Lilly vs Novo Nordisk Q3 2026: Lilly Mounjaro and Zepbound Lift Q3 2026 Revenue 39% to $24.4 Billion as Novo Nordisk Wegovy Pill Adds DKK 5.4 Billion
Eli Lilly vs Novo Nordisk Q3 2026: Lilly revenue rose 39% to $24.4 billion on Mounjaro and Zepbound, while Novo Nordisk adjusted sales grew 4% at CER. Both raised 2026 guidance. See the side-by-side data.
Gilead Lenacapavir PURPOSE 5 Data: Twice-Yearly Yeztugo Reaches 85.6% PrEP Persistence Versus 46.3% for Daily F/TDF
Gilead Lenacapavir PURPOSE 5 results show 85.6% of participants on twice-yearly lenacapavir stayed persistent on PrEP at Week 52, versus 46.3% on daily oral F/TDF, with zero HIV acquisitions in the lenacapavir arm.
Novo Nordisk Q3 2026 Results: Wegovy Pill Sales Hit DKK 5.4 Billion as Company Raises Full-Year Outlook
Novo Nordisk Q3 2026 results show Wegovy pill sales of DKK 5,394 million, adjusted operating profit up 27% at constant exchange rates, and a raised 2026 outlook. The report also covers CagriSema data, DKK 8.7 billion of impairments and a CFO change.
Pfizer Q3 2026 Results: Pfizer Raises 2026 Guidance to $62–64 Billion as Launched Products Grow 32%
Pfizer Q3 2026 Results show $16.6 billion in revenue, 32% operational growth from launched and acquired products, and a raised 2026 outlook of $62.0–$64.0 billion. Pfizer also named Cecile Guegan as CFO and reported progress for Elrexfio, Litfulo, Talzenna and Tukysa.